Skin Basal Cell Carcinoma Tissue Array With Benign Nevus Tissue As Control, Including TNM, Stage And Pathology Grade, 50 Cases/ 100 Cores|ヒト組織アレイ
掲載日情報：2015/08/07 現在Webページ番号：173888
US Biomax社は、豊富なラインナップの組織アレイ、組織切片(凍結、FFPE)を提供しているメーカーです。
US Biomax社のヒト組織アレイ(Skin Basal Cell Carcinoma Tissue Array With Benign Nevus Tissue As Control, Including TNM, Stage And Pathology Grade, 50 Cases/ 100 Cores)をご紹介します。
※ヒト組織アレイは、ドナーからインフォームドコンセントを取得した組織を使用しています。
※ドナーの組織は、HIV、Hepatitis B、Hepatitis Cが陰性であることを確認しています。
※本製品は研究用です。研究用以外には使用できません。
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの価格
[在庫・価格 ：2025年04月29日 10時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Skin basal cell carcinoma tissue array with benign nevus tissue as control, including TNM, stage and pathology grade・・・ |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 ：2025年04月29日 10時55分現在]
※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
Skin basal cell carcinoma tissue array with benign nevus tissue as control, including TNM, stage and pathology grade・・・
文献数： 0
- 商品コード：SK803a
- メーカー：USB
- 包装：1slide
- 価格：¥68,000
- 在庫：無(未発注)
- 納期：2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等：
| 説明文 | |||
|---|---|---|---|
| 法規制等 | |||
| 保存条件 | 4℃ | 法規備考 | |
| 掲載カタログ |
|
||
| 製品記事 | TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド |
||
| 関連記事 | TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして |
||
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの特長
| Microarray Panel: | Skin basal cell carcinoma tissue microarray with benign nevus tissue, containing 30 cases of basal cell carcinoma, 20 cases of benign nevus, duplicate cores per case | |
|---|---|---|
| Cores: | 100 | |
| Cases: | 50 | |
| Layout: | 10 cols × 10 rows | |
| Core Diameter: | 1 mm | |
| Thickness: | 5 µm | |
| Applications: | Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page. |
|
| Notes: | Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure. | |
*Tissue Microarray Slide Types:
- Unstained: unstained paraffin tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H and E: Hematoxylin and Eosin stained tissue array slide.
カートに商品を
追加しました。
追加しました。
ヒト組織アレイの仕様表
| Pos | No. | Sex | Age | Organ | Pathology diagnosis | Stage | TNM | Type † |
|---|---|---|---|---|---|---|---|---|
| A1 | 1 | M | 57 | Skin | Basal cell carcinoma of scalp (sparse) | II | T2bN0M0 | Malignant |
| A2 | 2 | M | 57 | Skin | Basal cell carcinoma of scalp | II | T2bN0M0 | Malignant |
| A3 | 3 | M | 61 | Skin | Basal cell carcinoma of left face | II | T2N0M0 | Malignant |
| A4 | 4 | M | 61 | Skin | Basal cell carcinoma of left face | II | T2N0M0 | Malignant |
| A5 | 5 | M | 53 | Skin | Basal cell carcinoma of scalp | I | T1N0M0 | Malignant |
| A6 | 6 | M | 53 | Skin | Basal cell carcinoma of scalp | I | T1N0M0 | Malignant |
| A7 | 7 | M | 61 | Skin | Basal cell carcinoma of left face | II | T2N0M0 | Malignant |
| A8 | 8 | M | 61 | Skin | Basal cell carcinoma of left face | II | T2N0M0 | Malignant |
| A9 | 9 | M | 75 | Fibrous tissue | Basal cell carcinoma of right groin | I | T1N0M0 | Malignant |
| A10 | 10 | M | 75 | Fibrous tissue | Basal cell carcinoma of right groin | I | T1N0M0 | Malignant |
| B1 | 11 | M | 60 | Skin | Basal cell carcinoma of left face | I | T1N0M0 | Malignant |
| B2 | 12 | M | 60 | Skin | Basal cell carcinoma of left face | I | T1N0M0 | Malignant |
| B3 | 13 | F | 75 | Skin | Basal cell carcinoma of right ear | III | T2N1M0 | Malignant |
| B4 | 14 | F | 75 | Skin | Basal cell carcinoma of right ear | III | T2N1M0 | Malignant |
| B5 | 15 | F | 50 | Breast | Basal cell carcinoma of left nipple | IIIB | T4N0M0 | Malignant |
| B6 | 16 | F | 50 | Breast | Basal cell carcinoma of left nipple | IIIB | T4N0M0 | Malignant |
| B7 | 17 | F | 80 | Skin | Basal cell carcinoma of scalp | I | T1N0M0 | Malignant |
| B8 | 18 | F | 80 | Skin | Basal cell carcinoma of scalp | I | T1N0M0 | Malignant |
| B9 | 19 | F | 65 | Tongue | Basal cell carcinoma of right parotid gland | IVA | T3N1M0 | Malignant |
| B10 | 20 | F | 65 | Tongue | Basal cell carcinoma of right parotid gland | IVA | T3N1M0 | Malignant |
| C1 | 21 | F | 60 | Vulva | Basal cell carcinoma of left labia majora | III | T4N0M0 | Malignant |
| C2 | 22 | F | 60 | Vulva | Basal cell carcinoma of left labia majora | III | T4N0M0 | Malignant |
| C3 | 23 | F | 70 | Vulva | Basal cell carcinoma of mons pubis | III | T4N0M0 | Malignant |
| C4 | 24 | F | 70 | Vulva | Basal cell carcinoma of mons pubis | III | T4N0M0 | Malignant |
| C5 | 25 | M | 64 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| C6 | 26 | M | 64 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| C7 | 27 | F | 63 | Skin | Basal cell carcinoma of right neck | II | T2N0M0 | Malignant |
| C8 | 28 | F | 63 | Skin | Basal cell carcinoma of right neck | II | T2N0M0 | Malignant |
| C9 | 29 | M | 62 | Skin | Basal cell carcinoma of right temporal | III | T4N0M0 | Malignant |
| C10 | 30 | M | 62 | Skin | Basal cell carcinoma of right temporal | III | T4N0M0 | Malignant |
| D1 | 31 | M | 62 | Skin | Basal cell carcinoma of left chest | II | T2N0M0 | Malignant |
| D2 | 32 | M | 62 | Skin | Basal cell carcinoma of left chest | II | T2N0M0 | Malignant |
| D3 | 33 | F | 74 | Skin | Basal cell carcinoma of right frontal | II | T2N0M0 | Malignant |
| D4 | 34 | F | 74 | Skin | Basal cell carcinoma of right frontal | II | T2N0M0 | Malignant |
| D5 | 35 | M | 58 | Skin | Basal cell carcinoma of back (chronic inflammation of fibrous tissue) | I | T1N0M0 | Malignant |
| D6 | 36 | M | 58 | Skin | Basal cell carcinoma of back (chronic inflammation of fibrous tissue) | I | T1N0M0 | Malignant |
| D7 | 37 | M | 70 | Skin | Basal cell carcinoma of right back | II | T2N0M0 | Malignant |
| D8 | 38 | M | 70 | Skin | Basal cell carcinoma of right back | II | T2N0M0 | Malignant |
| D9 | 39 | M | 55 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| D10 | 40 | M | 55 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| E1 | 41 | F | 85 | Skin | Basal cell carcinoma of nose | II | T2N0M0 | Malignant |
| E2 | 42 | F | 85 | Skin | Basal cell carcinoma of nose | II | T2N0M0 | Malignant |
| E3 | 43 | M | 82 | Skin | Basal cell carcinoma of right oxter | II | T3N0M0 | Malignant |
| E4 | 44 | M | 82 | Skin | Basal cell carcinoma of right oxter | II | T3N0M0 | Malignant |
| E5 | 45 | F | 84 | Skin | Basal cell carcinoma of right neck | II | T2N0M0 | Malignant |
| E6 | 46 | F | 84 | Skin | Basal cell carcinoma of right neck | II | T2N0M0 | Malignant |
| E7 | 47 | F | 47 | Skin | Basal cell carcinoma of tempus | I | T1N0M0 | Malignant |
| E8 | 48 | F | 47 | Skin | Basal cell carcinoma of tempus (skeletal muscle tissue) | I | T1N0M0 | Malignant |
| E9 | 49 | M | 80 | Skin | Basal cell carcinoma of left leg | I | T1N0M0 | Malignant |
| E10 | 50 | M | 80 | Skin | Basal cell carcinoma of left leg | I | T1N0M0 | Malignant |
| F1 | 51 | M | 75 | Skin | Basal cell carcinoma of occipital | II | T2N0M0 | Malignant |
| F2 | 52 | M | 75 | Skin | Basal cell carcinoma of occipital | II | T2N0M0 | Malignant |
| F3 | 53 | F | 54 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| F4 | 54 | F | 54 | Skin | Basal cell carcinoma of scalp | II | T2N0M0 | Malignant |
| F5 | 55 | F | 82 | Skin | Basal cell carcinoma of frontal | I | T1N0M0 | Malignant |
| F6 | 56 | F | 82 | Skin | Basal cell carcinoma of frontal | I | T1N0M0 | Malignant |
| F7 | 57 | M | 36 | Ear | Basal cell carcinoma of right ear | I | T1N0M0 | Malignant |
| F8 | 58 | M | 36 | Ear | Basal cell carcinoma of right ear (sparse) | I | T1N0M0 | Malignant |
| F9 | 59 | F | 62 | Skin | Basal cell carcinoma of right face (sparse) | I | T1N0M0 | Malignant |
| F10 | 60 | F | 62 | Skin | Basal cell carcinoma of right face | I | T1N0M0 | Malignant |
| G1 | 61 | F | 30 | Skin | Intradermal nevus of right buttock | – | – | Benign |
| G2 | 62 | F | 30 | Skin | Intradermal nevus of right buttock | – | – | Benign |
| G3 | 63 | M | 50 | Skin | Compound nevus of upper arm | – | – | Benign |
| G4 | 64 | M | 50 | Skin | Compound nevus of upper arm | – | – | Benign |
| G5 | 65 | F | 29 | Skin | Compound nevus of left shoulder | – | – | Benign |
| G6 | 66 | F | 29 | Skin | Compound nevus of left shoulder | – | – | Benign |
| G7 | 67 | M | 35 | Skin | Sebaceous nevus of right tempus | – | – | Benign |
| G8 | 68 | M | 35 | Skin | Sebaceous nevus of right tempus | – | – | Benign |
| G9 | 69 | F | 35 | Skin | Intradermal nevus of chest wall | – | – | Benign |
| G10 | 70 | F | 35 | Skin | Intradermal nevus of chest wall | – | – | Benign |
| H1 | 71 | F | 23 | Skin | Compound nevus of right waist (appendix tissue) | – | – | Benign |
| H2 | 72 | F | 23 | Skin | Compound nevus of right waist (appendix tissue) | – | – | Benign |
| H3 | 73 | M | 25 | Skin | Compound nevus of left leg | – | – | Benign |
| H4 | 74 | M | 25 | Skin | Compound nevus of left leg | – | – | Benign |
| H5 | 75 | M | 20 | Skin | Intradermal nevus of left shoulder | – | – | Benign |
| H6 | 76 | M | 20 | Skin | Intradermal nevus of left shoulder | – | – | Benign |
| H7 | 77 | M | 38 | Skin | Intradermal nevus of right face | – | – | Benign |
| H8 | 78 | M | 38 | Skin | Intradermal nevus of right face | – | – | Benign |
| H9 | 79 | M | 62 | Skin | Junction nevus of chest wall | – | – | Benign |
| H10 | 80 | M | 62 | Skin | Junction nevus of chest wall | – | – | Benign |
| I1 | 81 | F | 10 | Skin | Compound nevus of right foot | – | – | Benign |
| I2 | 82 | F | 10 | Skin | Compound nevus of right foot | – | – | Benign |
| I3 | 83 | F | 34 | Skin | Sebaceous nevus of head | – | – | Benign |
| I4 | 84 | F | 34 | Skin | Sebaceous nevus of head | – | – | Benign |
| I5 | 85 | F | 2 | Skin | Intradermal nevus of face | – | – | Benign |
| I6 | 86 | F | 2 | Skin | Intradermal nevus of face | – | – | Benign |
| I7 | 87 | M | 32 | Skin | Sebaceous nevus of right elbow | – | – | Benign |
| I8 | 88 | M | 32 | Skin | Sebaceous nevus of right elbow | – | – | Benign |
| I9 | 89 | M | 6 Mon. | Skin | Intradermal nevus of face | – | – | Benign |
| I10 | 90 | M | 6 Mon. | Skin | Intradermal nevus of face | – | – | Benign |
| J1 | 91 | M | 39 | Skin | Compound nevus of scalp | – | – | Benign |
| J2 | 92 | M | 39 | Skin | Compound nevus of scalp | – | – | Benign |
| J3 | 93 | M | 11 | Skin | Pigmented intradermal nevus | – | – | Benign |
| J4 | 94 | M | 11 | Skin | Pigmented intradermal nevus | – | – | Benign |
| J5 | 95 | F | 2 | Skin | Intradermal nevus of right leg | – | – | Benign |
| J6 | 96 | F | 2 | Skin | Intradermal nevus of right leg | – | – | Benign |
| J7 | 97 | M | 50 | Skin | Skin tissue | – | – | Normal |
| J8 | 98 | M | 50 | Skin | Skin tissue | – | – | Normal |
| J9 | 99 | M | 2 Mon. | Skin | Skin tissue of head | – | – | Normal |
| J10 | 100 | M | 2 Mon. | Skin | Skin tissue of head | – | – | Normal |
| – | – | M | 42 | Adrenal gland | Pheochromocytoma (tissue marker) | Malignant |
*For precise diagnosis, refer to pathology description.
カートに商品を
追加しました。
追加しました。
ヒト組織アレイのFAQ
カートに商品を
追加しました。
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。